The company attributed the increase to financial reserves and a $174 million shift in its stock value, according to the report.
The recall for its Rejuvenate and ABG II modular-neck hip devices began in June of 2012 because of a risk for metal corrosion.
More Articles on Devices:
AxoGen to Present Hand Graft Clinical Results at Hand Surgery Conference
GE Capital Invests $21.5M for Amedica Spine Device Development
38 Orthopedic & Spine Devices Receive FDA 510(k) Clearance in December
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.